Develops cell therapy platforms for cancer and other diseases, and provides marketing software and workflow tools for business customers.
10-K for FY2025, filed Mar 19, 2026
The company serves customers through data research and advertising campaigns delivered via cold emails and social media, plus webinars for targeted business-to-business audiences.
10-K for FY2025, filed Mar 19, 2026The Company generates revenue from its customers by 1) performing data research for its customers and delivering advertising campaigns via…View ↗
8-K, filed Sep 14, 2026
On September 8, 2026 (the “Closing Date”), the Company completed the Transaction. At the closing of the Transaction (the “Closing”), Seller…View ↗
Expanded GEAR rights
The earlier report described shared co-development rights to GEAR-NK; the latest report says the company obtained exclusive worldwide development and commercialization rights to the GEAR Cell Therapy Platform.
10-K for FY2022, filed Mar 29, 2023 10-K for FY2025, filed Mar 19, 2026In connection with the Vy-Gen relationship and the Company’s rights in respect of the two product candidates described above, in December…View ↗
In March 2025, the Company reached an agreement with Vy-Gen-Bio, Inc. (“Vy-Gen”) to successfully license the exclusive worldwide…View ↗
Added software tools
The earlier report focused on developing its product portfolio through therapeutic partnerships; the latest description also includes marketing software and robotic process automation tools for business operations.
10-K for FY2022, filed Mar 29, 2023 10-K for FY2025, filed Mar 19, 2026Our current business model is designed around furthering the development of our current product portfolio. We are continually exploring…View ↗
Coeptis is a biopharmaceutical and technology company. The biopharmaceutical division focuses on developing innovative cell therapy…View ↗
Loading...